相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 供应商:
上海联迈生物工程有限公司
- 库存:
大量
- 靶点:
详见说明书
- 级别:
1
- 目录编号:
LM-6194R-FITC
- 克隆性:
多克隆
- 抗原来源:
Rabbit
- 保质期:
1年
- 抗体英文名:
Anti-Sclerostin/FITC
- 抗体名:
Anti-Sclerostin/FITC
- 标记物:
FITC标记
- 宿主:
Human, Mouse, Rat, Dog, Pig, Horse, Rabbit,
- 适应物种:
Human, Mouse, Rat, Dog, Pig, Horse, Rabbit,
- 免疫原:
详见说明书
- 亚型:
IGg
- 形态:
粉末、液体、冻干粉
- 应用范围:
IF=1:50-200
- 浓度:
1mg/ml
- 保存条件:
-20 °C
- 规格:
100ul
| 英文名称 | Anti-Sclerostin/FITC |
| 中文名称 | FITC标记的骨形态发生抑制蛋白SOST抗体 |
| 别 名 | BEER; Cortical hyperostosis with syndactyly; Sclerosteosis; Sclerostin; SOST; SOST_HUMAN; VBCH. |
| 规格价格 | 100ul/2980元 购买 大包装/询价 |
| 说 明 书 | 100ul |
| 研究领域 | 信号转导 干细胞 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human, Mouse, Rat, Dog, Pig, Horse, Rabbit, |
| 产品应用 | IF=1:50-200 not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 21kDa |
| 性 状 | Lyophilized or Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Sclerostin |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 产品介绍 | background: Negative regulator of bone growth.Sclerostin (SOST) is a bone morphogenetic protein (BMP) antagonist, leading to the activation of BMP signaling. It negatively regulates the formation of bone by repressing the differentiation and/or function of osteoblasts induced by BMPs. It has been shown that Sclerostin binds BMP-5, -6, and -7 with high affinity and BMP-2 and -4 with low affinity. The noggin-sclerostin protein complex represents a novel mechanism for the fine-tuning of BMP activity in bone homeostasis. Evidence is accumulating that one of the important mechanisms of bone regulation by sclerostin is the modulation of Wnt/Beta-catenin signaling. Sclerostin also rapidly activated ERK-1/2 MAPK signaling, indicating the involvement of additional signaling pathways. Function: Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation. Subunit: Interacts with LRP4 (via the extracellular domain); the interaction facilitates the inhibition of Wnt signaling. Interacts with LRP5 (via the first two YWTD-EGF repeat domains); the interaction inhibits Wnt-mediated signaling. Interacts with LRP6. Subcellular Location: Secreted. Tissue Specificity: Widely expressed at low levels with highest levels in bone, cartilage, kidney, liver, bone marrow and primary osteeoblasts differentiated for 21 days. DISEASE: Defects in SOST are the cause of sclerosteosis type 1 (SOST1) [MIM:269500]. An autosomal recessive sclerosing bone dysplasia characterized by a generalized hyperostosis and sclerosis leading to a markedly thickened skull, with mandible, ribs, clavicles and all long bones also being affected. Due to narrowing of the foramina of the cranial nerves, facial nerve palsy, hearing loss and atrophy of the optic nerves can occur. Sclerosteosis is clinically and radiologically very similar to van Buchem disease, mainly differentiated by hand malformations and a large stature in sclerosteosis patients. Defects in SOST are a cause of van Buchem disease (VBCH) [MIM:239100]. An autosomal recessive sclerosing bone dysplasia characterized by endosteal hyperostosis of the mandible, skull, ribs, clavicles, and diaphyses of the long bones. Affected patients present a symmetrically increased thickness of bones, most frequently found as an enlarged jawbone, but also an enlargement of the skull, ribs, diaphysis of long bones, as well as tubular bones of hands and feet. The clinical consequence of increased thickness of the skull include facial nerve palsy causing hearing loss, visual problems, neurological pain, and, very rarely, blindness as a consequence of optic atrophy. Serum alkaline phosphatase levels are elevated. Note=A 52 kb deletion downstream of SOST results in SOST transcription suppression causing van Buchem disease. Defects in SOST are a cause of craniodiaphyseal dysplasia autosomal dominant (CDD) [MIM:122860]. A severe bone dysplasia characterized by massive generalized hyperostosis and sclerosis, especially involving the skull and facial bones. The sclerosis is so severe that the resulting facial distortion is referred to as 'leontiasis ossea' (leonine faces) and the bone deposition results in progressive stenosis of craniofacial foramina. Respiratory obstruction due to choanal stenosis compromises the clinical outcomes of affected patients. Note=Heterozygous mutations located in the secretion signal of the SOST gene prevent sclerostin secretion and can be responsible for craniodiaphyseal dysplasia. Similarity: Belongs to the sclerostin family. Contains 1 CTCK (C-terminal cystine knot-like) domain. Database links: Entrez Gene: 50964 Human Entrez Gene: 74499 Mouse Omim: 605740 Human SwissProt: Q9BQB4 Human SwissProt: Q99P68 Mouse Unigene: 349204 Human Unigene: 265602 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验色,或核呈分叶状,边集的Hoechst着色的为调亡细胞。我最近在作的试验就是用的这种方法,附上一张我染的PC12细胞的图片,请大家指教。更精确的定量可以通过流式细胞仪来检测。用PI和Hoechst33342双标鉴别调亡、坏死,这种方法简便易行,结果比较可靠。 2、PI和Calcein-Am双标: Calcein-AM 是一种绿色荧光标记物,可显示胞浆,为膜通透性的荧光染料。Calcein-AM 一旦进入胞内,便可被内源性酯酶水解成绿色荧光物质calcein, 并保留在胞浆中。细胞
+成纤维细胞在心脏细胞的特殊定位。研究结果表明,mir-16-2-3p 在各种主要细胞类型之间的表达相似。此外,研究人员还将慢病毒注射进 db/db 小鼠心脏内,结果发现小鼠静脉注射 FITC 标记的凝集素显示 Micro 组的微循环改善,这也表明了 db/ db 小鼠心脏中 mir-16-2-3p 的过表达与心脏改善功能、纤维化和微循环存在联系。 图 3 来自 DM、DM-CMD 和 DM-CAD 的血清来源的外泌体的分离和表征(图源:[3]) 4. 二型糖尿病病损肝脏来源的外泌体通过 Fasn
)注意事项 第三章 免疫荧光细胞化学技术 第一节 免疫荧光细胞化学的原理 一、直接法 二、间接法 三、补体法 四、双重免疫荧光标记法 五、对照试验 第二节 荧光抗体的制备 一、荧光素 (一)异硫氰酸荧光素(FITC) (二)四乙基罗达明(RB200) (三)四甲基异硫氰酸罗达明(TMRITC) 二、荧光素标记抗体的方法 (一)FITC标记抗体的方法 (二)四乙罗达明标记抗体方法 (三)四甲基异硫氰酸罗达明标记抗体方法 (四)藻红蛋白标记抗体方法 (五)PE
技术资料暂无技术资料 索取技术资料









